OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Instagram Outage Disrupts Thousands of U.S. Users 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
NEW YORK, March 28, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Aratana Therapeutics, Inc. (NASDAQ:PETX) between March 16, 2015 and February 3, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Dezi v. Aratana Therapeutics, Inc., et al. (Case No. 1:17-cv-01446) in the USDC for the Southern District of New York. To get more information go to:
http://www.zlk.com/pslra/aratana-therapeutics-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Aratana did not have manufacturing contracts in place sufficient to support manufacturing of ENTYCE at a commercial scale; (2) therefore, ENTYCE was not likely to be commercially available until late 2017; (3) accordingly, Aratana had misled investors regarding the probable timeline for a commercial launch of ENTYCE; and (4) consequently, Aratana’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Aratana you have until April 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
